Oxaliplatin was brought into clinical evaluation in ovarian cancer because of the in vitro and in vivo antitumor activity observed in experimental models resistant to cisplatin. As single agent at 130 mg/m2 every 3 weeks, the objective response rates rage from 16% to 29% in patients treated after failure of one or two regimens. As first line, in a randomized trial cyclophosphamide-cisplatin versus cyclophosphamide-oxaliplatine, no significant statistical differences were observed in efficacy parameters (response rate, progression free survival and overall survival). The toxicity profile seemed to favor the oxaliplatin arm. Many associations with other available active drugs as taxanes, gemcitabine and liposomal doxorubicin were performed with promising results.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Combination of cowpea mosaic virus (CPMV) intratumoral therapy and oxaliplatin chemotherapy.
Mater Adv
June 2024
Department of NanoEngineering, University of California San Diego, 9500 Gilman Dr, La Jolla, California 92093, USA.
Article Synopsis
- - Cowpea mosaic virus (CPMV) has shown effectiveness as an immunotherapy for tumors in preclinical and canine trials, prompting exploration of combination treatments to enhance its efficacy.
- - A study combining CPMV with the chemotherapy drug oxaliplatin significantly improved survival rates and reduced tumor size in mouse models of ovarian and melanoma cancers, outperforming each treatment alone.
- - The therapy worked by activating immune responses and modulating the tumor environment, highlighting the potential for combining CPMV with traditional chemotherapy in future clinical applications.
Extremely rare mucinous adenocarcinoma of the small bowel causing bilateral metastatic Kukenberg tumors of the ovaries: A case report.
Medicine (Baltimore)
November 2024
Affiliated Hospital of North China University of Science and Technology, Gastrointestinal Oncology Treatment Center, Tangshan, Hebei, China.
Rationale: Small bowel adenocarcinoma (SBA) is an extremely rare tumor that is not fully understood, SBA accounts for less than 5% of gastrointestinal cancers, Krukenberg tumors account for a lower proportion of all ovarian tumors, close to 2%. Stomach is the most common primary site of Krukenberg tumor. The phenomenon of bilateral ovarian Kukenberg tumor caused by implantation and metastasis of small bowel cancer is extremely rare, with few literature reports and limited clinical diagnosis and treatment data.
View Article and Find Full Text PDFSynchronous gastric and ovarian cancer successfully treated with FOLFOX therapy: a case report and review of the literature.
Int Cancer Conf J
October 2024
Department of Diagnostic Pathology, Kyoto-Katsura Hospital, 17 Yamada Hirao-cho, Nishikyo-ku, Kyoto-shi, Kyoto, 615-8256 Japan.
Synchronous gastric and ovarian cancer is extremely rare, and there have been no case reports. Here, we present the first case of synchronous gastric and ovarian cancer successfully treated with chemotherapy and surgery. A 72-year-old Japanese woman presented at our hospital with upper abdominal pain and vomiting.
View Article and Find Full Text PDFRAS mutant transverse colon cancer with multiple liver metastases achieving long-term disease-free survival with postoperative maintenance therapy with aflibercept + FOLFIRI and four repeated radical resections: a case report.
Surg Case Rep
October 2024
Department of Surgery and Science, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Article Synopsis
- The management of colorectal liver metastases (CRLMs) requires a team approach, with debates over the use of angiogenesis inhibitors for RAS mutant tumors.
- A case study of a 37-year-old woman with RAS mutant transverse colon cancer showed long-term disease-free survival through multiple surgeries and the combination treatment of aflibercept and FOLFIRI.
- The findings suggest that a multidisciplinary strategy focused on complete tumor resection, along with the use of aflibercept, can successfully manage recurrent CRLMs and offer extended survival rates.
Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications.
Cancer Sci
November 2024
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Pancreatic ductal adenocarcinoma (PDAC) poses significant challenges due to its high mortality, making it a critical area of research. This retrospective observational study aimed to analyze real-world data from comprehensive genome profiling (CGP) of Japanese patients with PDAC, mainly focusing on differences in gene detection rates among panels and the implications for homologous recombination deficiency (HRD) status. This study enrolled 2568 patients with PDAC who had undergone CGP between June 2019 and December 2021 using data from the nationwide Center for Cancer Genomics and Advanced Therapeutics database.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!